Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance

Diabetes

Volumn 54, Issue 5, 2005, Pages 1566-1572

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; INSULIN SENSITIZING AGENT; METFORMIN; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; TREATMENT OUTCOME; WEIGHT REDUCTION;

BLOOD COAGULATION; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INFLAMMATION; LIFE STYLE; MALE; METFORMIN; MIDDLE AGED; OBESITY;

EID: 17844366621     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.5.1566     Document Type: Article

References (36)

1. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
2. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK: Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 263:2893-2898, 1990
3. Fagot-Campagna A, Narayan KM, Hanson RL, Imperatore G, Howard BV, Nelson RG, Pettitt DJ, Knowler WC: Plasma lipoproteins and incidence of non-insulin-dependent diabetes mellitus in Pima Indians: protective effect of HDL cholesterol in women. Atherosclerosis 128:113-119, 1997
4. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM: Elevated levels of acute phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes 51:1131-1137, 2002
5. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE: Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25:1129-1134, 2002
6. Mykkänen L, Laakso M, Penttilä I, Pyörälä K. Asymptomatic hyperglycemia and cardiovascular risk factors in the elderly. Atherosclerosis 88:153-161, 1991
7. Rodriguez BL, Curb JD, Burchfiel CM, Huang B, Sharp DS, Lu GY, Fujimoto W, Yano K: Impaired glucose tolerance, diabetes, and cardiovascular risk factor profiles in the elderly: the Honolulu Heart Program. Diabetes Care 19:587-590, 1996
8. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Hamman RF: Predictors of progression from impaired glucose tolerance to non-insulin dependent diabetes: an analysis of six prospective studies. Diabetes 46:701-710, 1997
9. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 22:920-924, 1999
10. Haffner SM: Impaired glucose tolerance: is it relevant for cardiovascular disease? Diabetologia 40 (Suppl. 2):S138-S140, 1997
11. Blake GJ, Ridker PM: Novel clinical markers of vascular wall inflammation. Circ Res 89:763-771, 2001
12. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation 102:42-47, 2000
13. Festa A, D'Agostino R Jr, Mykkanen L, Tracy RP, Zaccaro DJ, Hales CN, Haffner SM: Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 19:562-568, 1999
14. Visser M, Bouter L, McQuillan G, Wener M, Harris T: Elevated C-reactive protein levels in overweight and obese adults. JAMA 282:2131-2135, 1999
15. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. Arterioscler Thromb Vasc Biol 19:972-978, 1999
16. Pradhan AD, Manson JE, Rifai N, Mykkanen L, Tracy RP, Haffner SM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327-334, 2001
17. Bastard J-P, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B: Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 85:3338-3342, 2000
18. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, D'Andrea F, Molinari AM, Giugliano D: Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 105:804-809, 2002
19. Marckmann P, Toubro S, Astrup A: Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. Eur J Clin Nutr 52:329-333, 1998
20. Van Den Burg PJM, Hospers JEH, Van Vliet M, Mosterd WL, Bouma BN, Huisveld IA: Effect of endurance training and seasonal fluctuation on coagulation and fibrinolysis in young sedentary men. J Appl Physiol 82:613-620, 1997
21. Haffner SM, Greenberg A, Weston W, Chen H, Williams K, Freed M: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106:679-684, 2002
22. phox subunit expression in mononuclear cells (MNC) and reduces C-reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1): evidence of a potent anti-inflammatory effect (Abstract). Diabetes 50 (Suppl. 2):A68, 2001
23. Chu NV, Kong APS, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD: Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 25:542-549, 2002
24. The Diabetes Prevention Program Research Group: The Diabetes Prevention Program: design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623-634, 1999
25. The Diabetes Prevention Program Research Group: reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 246:393-403, 2002
26. Bureau of the Census: Census of the Population, 1990. Washington, DC, U.S. Govt. Printing Office, 1990 (OMB 0607-0628)
27. Matthews DP, Hosker JP, Rudenski AS, Naylor GA, Treacher DF, Turner RL: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
28. Diggle PJ, Liang K-Y, Zeger SL. Analysis of Longitudinal Data. New York, Oxford Univ. Press, 1994
29. Tchernof A, Nolan A, Sites C, Aders P, Poehlman E: Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation 105:564-569, 2002
30. Jialal I, Stein D, Balls D, Grundy SM, Adams-Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103:1933-1935, 2001
31. Ridker P, Rifai N, Rose L, Buring J, Cook N: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557-1565, 2002
32. Festa A, Hanley AJG, Tracy RP, D'Agostino R, Haffner SM: Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 108:1822-1830, 2003
33. Verma S, Wang, C-H, Li S-R Dumont AS, Fedak PWM, Badiwala MV, Dhillon B, Weisel RD, Li R-K, Mickle DAG, Stewart DJ: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106:913-919, 2002
34. Pasceri V, Chang J, Willerson JT, Yeh ETH: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103:2031-2534, 2001
35. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JMC: Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci 98:531-535, 2000
36. Devaraj S, Xu DY, Jialal I: C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107:398-404, 2003